Repligen (NASDAQ:RGEN) Stock Price Down 4.8% – Here’s Why

Repligen Co. (NASDAQ:RGEN)’s share price fell 4.8% during trading on Friday . The stock traded as low as $133.33 and last traded at $135.54. 23,261 shares changed hands during trading, a decline of 96% from the average session volume of 657,365 shares. The stock had previously closed at $142.43.

Analyst Ratings Changes

A number of analysts recently commented on RGEN shares. Wolfe Research started coverage on Repligen in a research report on Thursday. They set a “peer perform” rating for the company. Benchmark reaffirmed a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. Finally, UBS Group lowered their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Repligen has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Performance

The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The firm has a market capitalization of $6.99 billion, a PE ratio of -337.11, a P/E/G ratio of 4.36 and a beta of 0.96. The company’s fifty day simple moving average is $141.09 and its 200 day simple moving average is $144.48.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The company had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the prior year, the company posted $0.23 EPS. Repligen’s revenue was up 9.7% compared to the same quarter last year. As a group, equities research analysts expect that Repligen Co. will post 1.44 EPS for the current fiscal year.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Hedge funds have recently bought and sold shares of the company. Andra AP fonden purchased a new stake in Repligen in the 2nd quarter worth approximately $25,000. Lazard Asset Management LLC grew its position in shares of Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 136 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. raised its position in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares in the last quarter. Finally, Resources Management Corp CT ADV bought a new stake in Repligen during the third quarter valued at $37,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.